Managing Director & Partner
Suchita Shah has worked at Boston Consulting Group since October of 2010. She is a core member of BCG’s Health Care practice and has significant experience in biopharma—specifically focused on market access, pricing, commercial strategy, and innovative growth. She is the lead for global value, access, and pricing in biopharmaceuticals.
Suchita helps clients with new product planning by supporting investment decisions and ensuring careful consideration of the relevant market and development drivers.
She supports due diligence efforts by quickly understanding new markets, unmet needs, and how to win. In her recent case work at BCG, Suchita also developed end-to-end disease area strategies to identify key areas for investment, led the strategy development for an imminent competitive threat, supported the US salesforce effectiveness effort to identify HCP value drivers, developed the brand positioning strategy for a launch drug entering a competitive class, and developed creative pricing, reimbursement, and access strategies for a drug entering a highly competitive class of drugs by building the narrative around value derived.
Before joining the firm, Suchita worked at Genentech, Abbott Vascular, and Eli Lilly in commercial and manufacturing roles.
Companies can take four steps to address the inequitable health outcomes that marginalized and underserved communities experience in the US.
BCG’s latest survey on the impact of COVID-19 shows which changes in how doctors engage with the pharma industry will last beyond the pandemic.
Payers are reluctant to cover quality-of-life therapies without evidence that they also lower costs. Companies can convince them by taking this five-step approach.
The pandemic has transformed health care. Physicians expect long-term changes in how they interact with biopharma companies.
“Double down on your loyalists”—and other insights to improve sales team efficiency.